Vimarsana
Biggest News Aggregation in the World

Chen Ruibang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chen Ruibang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chen Ruibang Today - Breaking & Trending Today

Bold, persistent reforms forge ahead under Xi's leadership - Vimarsana News

Bold, persistent reforms forge ahead under Xi's leadership

Bold, persistent reforms forge ahead under Xi's leadership Pub Date:20-12-18 08:42 Source:Xinhua Coronary stents, used to treat coronary heart disease, were once priced at about 13,000 yuan (1,989 U.S. dollars) each in China. Now they are expected to cost patients only 700 yuan on average. The massive price slash ensued from the initial round of the Chinese government's centralized procurement program for high-value medical consumables in early November. The program, which aims to bring down the pricing by large-scale purchasing and s...

Bold, persistent reforms forge ahead under Xi's leadership_GMW.cn - Vimarsana News

Bold, persistent reforms forge ahead under Xi's leadership_GMW.cn

2020-12-18 16:25   By: Xinhua   FUZHOU, Dec. 17 (Xinhua) -- Coronary stents, used to treat coronary heart disease, were once priced at about 13,000 yuan (1,989 U.S. dollars) each in China. Now they are expected to cost patients only 700 yuan on average. The massive price slash ensued from the initial round of the Chinese government's centralized procurement program for high-value medical consumables in early November. The program, which aims to bring down the pricing by large-scale purchasing and squeezing out multiple layers of agent middleme...

Source: en.gmw.cn
Bold, persistent reforms forge ahead under Xi's leadership - China News - Vimarsana News

Bold, persistent reforms forge ahead under Xi's leadership - China News

2020-12-18 02:11:15 GMT2020-12-18 10:11:15(Beijing Time) Xinhua English Coronary stents, used to treat coronary heart disease, were once priced at about 13,000 yuan (1,989 U.S. dollars) each in China. Now they are expected to cost patients only 700 yuan on average. The massive price slash ensued from the initial round of the Chinese government's centralized procurement program for high-value medical consumables in early November. The program, which aims to bring down the pricing by large-scale purchasing and squeezing out multiple layers of agent middlemen, owes its origin to Sanming, ...

Source: sina.com